Our CEO, Dr James Garner recently conducted video and print interviews with Share Café following the US Food and Drug Administration’s award of Rare Pediatric Disease Designation for paxalisib in Diffuse Intrinsic Pontine Glioma (DIPG) and Fast Track Designation for paxalisib in glioblastoma.

Our collaborator, Dr Matt Dun, and Kazia CEO, Dr James Garner, were interviewed on Channel 7’s Sunrise program on the development of paxalisib for Diffuse Intrinsic Pontine Glioma (DIPG) and the grant by the FDA of Rare Pediatric Disease Designation for paxalisib for the treatment of DIPG.

Our CEO, Dr James Garner recently had an article published in EQUITY magazine – the membership magazine for the Australian Shareholders Association.

This Glioblastoma (GBM) Awareness Day, Australian oncology-focused biotech company, Kazia calls for greater awareness of one of the most lethal brain cancers in the US.

Our CEO, Dr James Garner sat down with the Australian Shareholders Association to discuss the development of our lead candidate, paxalisib, for glioblastoma.

On World Brain Tumour Day (June 8), Kazia is calling for greater awareness of the signs and symptoms of brain tumours, as they can often be malignant and therefore, a potentially deadly condition.

As May draws to a close, we’d like to look back on World Ovarian Cancer Day, which was held on May 8.

Our CEO, Dr James Garner recently conducted an interview with FNN which focused on the recent interim data from Kazia’s ongoing phase II trial of paxalisib in glioblastoma.

Kazia CEO, Dr James Garner discusses the recent positive interim data from the ongoing phase II trial of paxalisib in glioblastoma, COVID-19 and the company's recent capital raising.

Kazia Therapeutics is pleased to make its March 2020 newsletter available to investors.

Our CEO, Dr James Garner sat down with Peter Switzer to discuss Kazia’s upcoming value-driving milestones in 2020 and the development of lead program, paxalisib, for Switzer Financial Group’s The CEO Masterclass series.

Our CEO, Dr James Garner sat down with Boardroom Media to discuss Kazia joining the GBM AGILE international phase II / III study in glioblastoma with its lead program, GDC-0084.

Our CEO, Dr James Garner was interviewed in BioWorld on the recent release of interim efficacy data from the phase II trial of GDC-0084 in glioblastoma as well as the overall GDC-0084 program.

Our Chief Executive Officer, Dr James Garner, sat down with Stuart Roberts of Pitt Street Research in Sydney to discuss the company’s recent announcement of positive interim efficacy data from its phase II trial of GDC-0084 in glioblastoma.

Kazia is pleased to invite investors to view an archived copy of CEO, Dr James Garner’s address from the company’s 2019 AGM, together with questions and answers relating to the presentation.

Our CEO, Dr James Garner, sat down with CommSec’s Tom Piotrowski recently to discuss the company’s recent $4 million capital raising as well as key data readouts from Kazia’s clinical trials.

Our Chief Executive Officer, Dr James Garner, sat down with Karen Tan from Proactive Investors in Sydney to discuss the company’s recent achievements and upcoming milestones.

Kazia Therapeutics is pleased to make its September 2019 newsletter available to investors.

Kazia has been named as a winner in the 2019 Australian and New Zealand Leadership Forum (ANZLF) Trans-Tasman Innovation & Growth Awards.

Our CEO, Dr James Garner recently presented an overview of the company as a guest speaker at the 2019 Gold Coast Investment Showcase.